These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26099344)

  • 61. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I; Prabhu SS
    Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey.
    Uehara R; Yashiro M; Oki I; Nakamura Y; Yanagawa H
    Pediatr Int; 2007 Aug; 49(4):427-30. PubMed ID: 17587262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunological abnormalities and endothelial cell injury in Kawasaki disease.
    Nonoyama S
    Acta Paediatr Jpn; 1991 Dec; 33(6):752-5. PubMed ID: 1801555
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X; Li CR; Yang J; Wang GB
    Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.
    Pierangeli SS; Espinola R; Liu X; Harris EN; Salmon JE
    Arthritis Rheum; 2001 Apr; 44(4):876-83. PubMed ID: 11315927
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Immunomodulatory effects of intravenous immunoglobulins].
    Kazatchkine M; Mouthon L; Kaveri SV
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S13-8. PubMed ID: 10896983
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment].
    Fu SF; Yu DL; Lv DY; Chen FY
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Jan; 16(1):44-7. PubMed ID: 24461177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. IVIg and LPS Co-stimulation Induces IL-10 Production by Human Monocytes, Which Is Compromised by an FcγRIIA Disease-Associated Gene Variant.
    Kozicky LK; Menzies SC; Zhao ZY; Vira T; Harnden K; Safari K; Del Bel KL; Turvey SE; Sly LM
    Front Immunol; 2018; 9():2676. PubMed ID: 30515163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immune Regulatory Functions of IgG in the Ontogeny of Human Natural Regulatory T Cells.
    Franco A
    Crit Rev Immunol; 2022; 42(2):29-33. PubMed ID: 37017286
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Kawasaki syndrome: role of superantigens revisited.
    Leung DYM; Schlievert PM
    FEBS J; 2021 Mar; 288(6):1771-1777. PubMed ID: 32770775
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pooled intravenous immunoglobulin in the management of systemic vasculitis.
    Jayne DR; Lockwood CM
    Adv Exp Med Biol; 1993; 336():469-72. PubMed ID: 8296659
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IL-1β and IL-17A are involved in IVIG resistance through activation of C/EBPβ and δ in a coronary artery model of Kawasaki disease.
    Inoue T; Miyashita M; Murakami S; Igarashi A; Motomura K; Abe J; Matsumoto K; Matsuda A
    Allergy; 2020 Aug; 75(8):2102-2105. PubMed ID: 32187376
    [No Abstract]   [Full Text] [Related]  

  • 73. Southwestern Internal Medicine Conference: high-dose intravenous gamma globulin therapy: how does it work?
    Smiley JD; Talbert MG
    Am J Med Sci; 1995 May; 309(5):295-303. PubMed ID: 7733144
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin.
    Maddur MS; Kaveri SV; Bayry J
    Trends Immunol; 2017 Nov; 38(11):789-792. PubMed ID: 28916232
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.
    Leung DY
    Clin Rev Allergy; 1992; 10(1-2):93-104. PubMed ID: 1606527
    [No Abstract]   [Full Text] [Related]  

  • 76. IVGG therapy in Kawasaki disease: mechanism(s) of action.
    Shulman ST
    Clin Immunol Immunopathol; 1989 Nov; 53(2 Pt 2):S141-6. PubMed ID: 2477184
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors.
    Shock A; Humphreys D; Nimmerjahn F
    J Allergy Clin Immunol; 2020 Sep; 146(3):492-500. PubMed ID: 32721416
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Kawasaki Disease: The Role of Immune Complexes Revisited.
    Menikou S; Langford PR; Levin M
    Front Immunol; 2019; 10():1156. PubMed ID: 31263461
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.
    Burns JC; Koné-Paut I; Kuijpers T; Shimizu C; Tremoulet A; Arditi M
    Arthritis Rheumatol; 2017 Feb; 69(2):268-276. PubMed ID: 27792871
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.
    Smith KG; Clatworthy MR
    Nat Rev Immunol; 2010 May; 10(5):328-43. PubMed ID: 20414206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.